A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas - 22/08/19
Anne Chang, MD, Stanford University School of Medicine, Stanford, CA; Duy Tran, BS, Stanford University School of Medicine, Stanford, CA; John Cannon, BS, Stanford University School of Medicine, Stanford, CA; Shufeng Li, MS, Stanford University School of Medicine, Stanford, CA; Mark Jeng, PhD, Stanford University School of Medicine, Stanford, CA; Kerri Rieger, MD, PhD, Stanford University School of Medicine, Stanford, CA; Sunil Reddy, MD, Stanford University School of Medicine, Stanford, CA; Kavita Sarin, MD, PhD, Stanford University School of Medicine, Stanford, CA; A. Dimitrios Colevas, MD, Stanford University School of Medicine, Stanford, CA
Le texte complet de cet article est disponible en PDF.| Merck, Sharp, and Dohme, Inc. provided funding for this study but were not involved in abstract submission, poster presentation, data collection, analysis, interpretation, trial design, patient recruitment or any other aspect. |
Vol 81 - N° 4S1
P. AB8 - octobre 2019 Retour au numéro
Article précédent
- A peak in the incidence of Kaposi sarcoma amongst black organ transplant recipients in London
- A potential association between frontal fibrosing alopecia and facial procedures
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?